Article info
PDFInterstitial lung disease
Original research
Potential for inhibition of checkpoint kinases 1/2 in pulmonary fibrosis and secondary pulmonary hypertension
- Correspondence to Dr Olivier Boucherat, Quebec Heart and Lung Institute Research Centre (IUCPQ), Quebec, QC G1V 4G5, Canada; olivier.boucherat{at}criucpq.ulaval.ca
Citation
Potential for inhibition of checkpoint kinases 1/2 in pulmonary fibrosis and secondary pulmonary hypertension
Publication history
- Received March 30, 2021
- Accepted June 21, 2021
- First published July 5, 2021.
Online issue publication
September 01, 2022
Article Versions
- Previous version (17 February 2022).
- You are viewing the most recent version of this article.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
© Author(s) (or their employer(s)) 2022. No commercial re-use. See rights and permissions. Published by BMJ.